Oncopeptides to Present Promising Phase I/ II Clinical Data at the European Hematology Association in Vienna, Austria, June 11 – 14 2015
Stockholm, Sweden June 4, 2015
Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – today announced that the clinical results from an ongoing Phase I/II study of safety and efficacy of melflufen and dexamethasone in patients with relapsed and relapsed-refractory multiple myeloma will be presented on poster P285 at the 20th European Hematology Association Congress in Vienna, in June.
The poster is entitled ‘Encouraging Preliminary Data in Ongoing Phase I/II study of Safety and Efficacy of Melflufen and Dexamethasone for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma’.
CEO, Jakob Lindberg commented “The results to date further support our belief that melflufen has the potential to be a pharmaceutical that makes a meaningful difference in the lives of patients, providing a reliable go-to alternative when conventional therapies have failed in relapsed-refractory multiple myeloma”.
Multiple myeloma is the second most common hematological cancer and worldwide more than 180,000 people are living with the disease, with approximately 86,000 new cases diagnosed annually (ref: International Agency for Research on Cancer).
The trial is being carried out across four centers in Europe (Sweden, Italy, the Netherlands and Denmark) and two in the USA (Boston, MA and Chapel Hill, NC).
If you would like to meet us at the meeting please contact:
Jakob Lindberg CEO
Oncopeptides AB, Stockholm, Sweden
Tel: +46 (0) 705 695 471
About Oncopeptides AB
Oncopeptides is a clinical stage pharmaceutical company developing oncology therapies centered around peptidase targeting.
Melflufen, Oncopeptides lead compound in clinical development, is a peptidase targeted therapy and a potent anti-angiogenetic compound. It triggers rapid, robust, and irreversible DNA damage and exerts it cytotoxicity through alkylation of DNA.
Many peptidases that are overexpressed in cancer cells, such as plasma cells in multiple myeloma, cleave melflufen so that the concentration of active compound increases at the most advantageous places within the diseased cells. This results in targeted delivery of the molecule and better treatment of the disease.
Oncopeptides is currently in the closing stages of a Phase II clinical trial with melflufen in patients with relapsed and relapsed-refractory multiple myeloma. The study is being carried out across six centers; in Sweden, Italy, the Netherlands, Denmark and the US (two sites) – with Dana Faber Cancer Institute, Boston, MA being the lead investigator site.